ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced the signing of a clinical supply agreement for its medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu/EndolucinBeta) with Y-mAbs Therapeutics, Inc. (Y-mAbs), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
Under the terms of the agreement, ITM will provide its n.c.a. 177Lu for the clinical development of Y-mAbs
